With the recent evidence that non-enhancing WHO grade II and III astrocytomas lacking the IDH1 mutation should be classified as glioblastoma (GBM) [10] and that not all high-grade gliomas enhance [11], there is a need to investigate other imaging technologies to better assess tumour burden. The gene discussed is IDH1; the disease is glioblastoma.